ArticleEmerging microbes & infections2025
Differential replication, pathology, and immune response of clade IIb mpox virus in C57BL/6 and BALB/c mice.
Article in Emerging microbes & infections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Differential pathogenesis and antiviral treatment outcomes of MPXV clade Ib and clade IIb in a BALB/c mouse model.Emerging microbes & infections · 2026Article
- Antifolate agent aminopterin demonstrates potent anti-monkeypox virus activityMicrobiology spectrum · 2026Article
- Mpox: disease manifestations and therapeutic development.Journal of virology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We have previously established a clade IIb mpox virus (MPXV) pathogenic BALB/c mouse model for developing mpox countermeasures. Here, we comprehensively investigated the susceptibility of BALB/c and C57BL/6 mice to MPXV and found that Clade IIb MPXV was capable of rapid replication in the lungs of both mouse strains, thus triggering similar dynamic pathological changes and antibody responses. However, C57BL/6 mice, compared to BALB/c mice, seem less susceptible to MPXV, evidenced by no significant weight loss, lower viral load, faster viral clearance, and earlier pathological improvement, as well as weaker antibody response. Interestingly, C57BL/6
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.